You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDyclonine
Accession NumberDB00645  (APRD00940)
TypeSmall Molecule
GroupsApproved
DescriptionDyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It is also found in some varieties of the Cepacol sore throat spray.
Structure
Thumb
Synonyms
1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone
2-(1-Piperidyl)ethyl P-butoxyphenyl ketone
3-Piperidino-4'-butoxypropiophenone
4-Butoxy-beta-piperidinopropiophenone
4-N-Butoxy-beta-(1-piperidyl)propiophenone
4'-Butoxy-3-piperidinopropiophenone
Diclonina
Dyclocaine
Dyclonin
Dyclonine
Dycloninum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cepacol Sore Throat SpraySpray0.1 %OralReckitt Benckiser (Canada) Inc1999-07-012012-03-23Canada
PeriorinseRinse.1 g/100mLDental; Oral; Topical; TransmucosalCentura Pharmaceuticals Inc2016-06-16Not applicableUs
Sore Throat ReliefLozenge3 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.Not applicableNot applicableCanada
Sucrets Black CherryLozenge3 mg/1OralInsight Pharmaceuticals LLC2009-06-18Not applicableUs
Sucrets Childrens CherryLozenge1.2 mg/1OralInsight Pharmaceuticals2009-07-28Not applicableUs
Sucrets Extra Strength Mint Flav.loz 3mgLozenge3 mgOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1994-12-311998-08-25Canada
Sucrets for KidsLozenge1.2 mgOralInsight Pharmaceuticals LLC1997-08-15Not applicableCanada
Sucrets for KidsLozenge1.2 mgOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1992-12-311998-08-25Canada
Sucrets Ms WintergreenLozenge3 mg/1OralInsight Pharmaceuticals2009-07-28Not applicableUs
Sucrets Regular Strength Lemon Flav.loz 2mgLozenge2 mgOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1994-12-311998-08-25Canada
Sucrets Regular Strength Lemon Flavoured LozengesLozenge2 mgOralHeritage Brands, A Subsidiary Of Insight Pharmaceuticals Llc1997-08-152009-06-19Canada
Sucrets Sore ThroatLozenge3 mgOralInsight Pharmaceuticals LLC2007-05-31Not applicableCanada
Sucrets Sore Throat Spray 0.1% CherryAerosol.1 %OralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1993-12-311996-09-12Canada
Sucrets Wild CherryLozenge2 mg/1OralInsight Pharmaceuticals LLC2009-07-28Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
DycloneAstraZeneca
SucretsInsight Pharmaceuticals
Brand mixtures
NameLabellerIngredients
Ambix First AidOrganics Corporation Of America Dba Ambix Laboratories
Benzethonium Chloride and Dyclonine HydrochlorideWalgreen Company
Benzethonium Chloride Plus Dyclonine HydrochlorideCVS Pharmacy
Cepacol Sore ThroatReckitt Benckiser LLC
Skin ShieldInsight Pharmaceuticals
Skin Shield Liquid BandageDel Pharmaceuticals Inc.
Sucrets CompleteInsight Pharmaceuticals LLC
Sucrets Complete Cool CitrusInsight Pharmaceuticals LLC
Sucrets Complete Sore Throat, Cough and IrritationInsight Pharmaceuticals LLC
Sucrets Complete Vapor CherryInsight Pharmaceuticals
Tanac Medicated GelDel Pharmaceutics (Canada) Inc.
Salts
Name/CASStructureProperties
Dyclonine hydrochloride
Thumb
  • InChI Key: KNZADIMHVBBPOA-UHFFFAOYSA-N
  • Monoisotopic Mass: 325.180856852
  • Average Mass: 325.873
DBSALT000651
Categories
UNII078A24Q30O
CAS number586-60-7
WeightAverage: 289.4125
Monoisotopic: 289.204179113
Chemical FormulaC18H27NO2
InChI KeyBZEWSEKUUPWQDQ-UHFFFAOYSA-N
InChI
InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3
IUPAC Name
1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one
SMILES
CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1
Pharmacology
IndicationUsed to provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures involving the esophagus, larynx, mouth, pharynx or throat, respiratory tract or trachea, urinary tract, or vagina. Also used to suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or intubation. Also used for relief of canker sores, cold sores or fever blister.
Structured Indications
PharmacodynamicsDyclonine is an oral anasthetic. If substantial quantities of local anesthetics are absorbed through the mucosa, actions on the central nervous system (CNS) may cause CNS stimulation and/or CNS depression. Actions on the cardiovascular system may cause depression of cardiac conduction and excitability and, with some of these agents, peripheral vasodilation.
Mechanism of actionLocal anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium channel protein type 10 subunit alphaProteinyes
inhibitor
HumanQ9Y5Y9 details
Related Articles
AbsorptionReadily absorbed through mucous membranes into the systemic circulation. The rate of absorption is influenced by the vascularity or rate of blood flow at the site of application, the total dosage (concentration and volume) administered, and the duration of exposure. Absorption from mucous membranes of the throat or respiratory tract may be especially rapid.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeApproximately 30 to 60 minutes.
ClearanceNot Available
ToxicitySymptoms of overdose include cardiovascular system depression, CNS toxicity, and methemoglobinemia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Dyclonine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Dyclonine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dyclonine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Azaperone.Vet Approved
AzelastineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Dyclonine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dyclonine is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dyclonine.Approved, Investigational
BuprenorphineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dyclonine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dyclonine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dyclonine.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dyclonine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dyclonine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dyclonine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dyclonine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Dyclonine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dyclonine.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dyclonine.Approved
CocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dyclonine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclobenzaprine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dyclonine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Dyclonine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dyclonine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Diazepam.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dyclonine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dyclonine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dyclonine is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dyclonine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dyclonine.Approved
EthanolDyclonine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dyclonine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dyclonine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dyclonine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Dyclonine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dyclonine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Hexobarbital.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dyclonine.Approved, Investigational
HydrocodoneDyclonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Indalpine.Investigational, Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Isoflurane.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dyclonine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dyclonine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dyclonine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Dyclonine is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Dyclonine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dyclonine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dyclonine.Approved
MethotrimeprazineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methylphenobarbital.Approved
MetyrosineDyclonine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Dyclonine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Investigational
MirtazapineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dyclonine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nalbuphine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dyclonine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Dyclonine is combined with Opium.Approved, Illicit
OrphenadrineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dyclonine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dyclonine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Paliperidone.Approved
ParaldehydeDyclonine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dyclonine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
PerazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dyclonine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pomalidomide.Approved
PramipexoleDyclonine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dyclonine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dyclonine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dyclonine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Dyclonine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Quetiapine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dyclonine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Romifidine.Vet Approved
RopiniroleDyclonine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dyclonine.Approved
RotigotineDyclonine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dyclonine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dyclonine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Dyclonine is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dyclonine.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dyclonine.Approved
SuvorexantDyclonine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptDyclonine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dyclonine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrodotoxin.Investigational
ThalidomideDyclonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dyclonine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dyclonine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dyclonine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Dyclonine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dyclonine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dyclonine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zolazepam.Vet Approved
ZolpidemDyclonine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Tianjiang Sun, Xiaohong Gu, Hongguo Lu, Min Chen, “Oral Preparation of Dyclonine Hydrochloride.” U.S. Patent US20080200506, issued August 21, 2008.

US20080200506
General ReferencesNot Available
External Links
ATC CodesN01BX02R02AD04
AHFS Codes
  • 52:16.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9856
Caco-2 permeable+0.7155
P-glycoprotein substrateSubstrate0.7596
P-glycoprotein inhibitor IInhibitor0.8077
P-glycoprotein inhibitor IINon-inhibitor0.6392
Renal organic cation transporterInhibitor0.7801
CYP450 2C9 substrateNon-substrate0.8107
CYP450 2D6 substrateNon-substrate0.5142
CYP450 3A4 substrateSubstrate0.5313
CYP450 1A2 substrateInhibitor0.8914
CYP450 2C9 inhibitorInhibitor0.793
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8574
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5388
Ames testNon AMES toxic0.7961
CarcinogenicityNon-carcinogens0.8823
BiodegradationNot ready biodegradable0.7106
Rat acute toxicity2.3661 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8071
hERG inhibition (predictor II)Inhibitor0.6351
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Astrazeneca lp
Packagers
Dosage forms
FormRouteStrength
CreamTopical
LiquidTopical
LiquidOral
SprayOral0.1 %
RinseDental; Oral; Topical; Transmucosal.1 g/100mL
LozengeOral3 mg/1
LozengeOral1.2 mg/1
LozengeOral
LozengeOral1.2 mg
LozengeOral2 mg
LozengeOral3 mg
AerosolOral.1 %
LozengeOral2 mg/1
GelTopical
Prices
Unit descriptionCostUnit
Dyclonine hcl powder4.9USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point174-175Bockstahler, E.R.; U.S.Patent 2,771,391; November 20,1956; assigned to Allied Laboratories, Inc. Florestano, H.J., Jeffries, S.F., Osborne, C.E. and Bahler, M.E.; U.S. Patent 2,868,689; January 13, 1959; assigned to Allied Laboratories, Inc.
water solubilitySoluble (HCl salt)Not Available
logP3.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.046 mg/mLALOGPS
logP4.11ALOGPS
logP3.68ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)15.88ChemAxon
pKa (Strongest Basic)8.36ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity87.07 m3·mol-1ChemAxon
Polarizability35.14 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Phenol ether
  • Benzoyl
  • Alkyl aryl ether
  • Piperidine
  • Beta-aminoketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Roghani S, Duperon DF, Barcohana N: Evaluating the efficacy of commonly used topical anesthetics. Pediatr Dent. 1999 May-Jun;21(3):197-200. [PubMed:10355012 ]
  4. Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. [PubMed:9476974 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23